{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:32:12Z","timestamp":1768278732202,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00277-017-2982-1","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T20:43:28Z","timestamp":1491597808000},"page":"1185-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in the treatment of relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"96","author":[{"given":"C.","family":"Shustik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bence-Bruckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Delage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L.","family":"Toze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"2982_CR1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164\u20131174","journal-title":"Lancet"},{"key":"2982_CR2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-C\u00e9ligny P et al (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756\u20131765","journal-title":"J Clin Oncol"},{"key":"2982_CR3","unstructured":"Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975\u20132013, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2013\/ , based on November 2015 SEER data submission, posted to the SEER web site, April 2016."},{"key":"2982_CR4","unstructured":"Statistics Canada. Table 103\u00ad0553: new cases and 1991 age\u00adstandardized rate for primary cancer (based on the August 2015 CCR tabulation file), by cancer type and sex, Canada, provinces and territories. Available at: http:\/\/www5.statcan.gc.ca\/cansim\/a26?lang=eng&id=1030553 . Accessed November 16, 2016."},{"issue":"Suppl 6","key":"2982_CR5","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","volume":"22","author":"B Eichhorst","year":"2011","unstructured":"Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, ESMO Guidelines Working Group (2011) Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi50\u2013vi54","journal-title":"Ann Oncol"},{"key":"2982_CR6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1309\/AJCPLIR4GZWX3XKA","volume":"139","author":"AJ Siddon","year":"2013","unstructured":"Siddon AJ, Rinder HM, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists (2013) Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. Am J Clin Pathol 139:708\u2013712","journal-title":"Am J Clin Pathol"},{"key":"2982_CR7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916","journal-title":"N Engl J Med"},{"key":"2982_CR8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaoncol.2015.0779","volume":"1","author":"C Nabhan","year":"2015","unstructured":"Nabhan C, Raca G, Wang YL (2015) Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol 1:965\u2013974","journal-title":"JAMA Oncol"},{"key":"2982_CR9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2008.399","volume":"23","author":"D Rossi","year":"2009","unstructured":"Rossi D, Lobetti Bodoni C, Genuardi E et al (2009) Telomere length is an independent predictor of survival, treatment requirement and Richter\u2019s syndrome transformation in chronic lymphocytic leukemia. Leukemia 23:1062\u20131072","journal-title":"Leukemia"},{"key":"2982_CR10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"The International CLL-IPI working group","year":"2016","unstructured":"The International CLL-IPI working group (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Onco 17:779\u2013790","journal-title":"Lancet Onco"},{"key":"2982_CR11","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D, International Workshop on Chronic Lymphocytic Leukemia et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","DOI":"10.1182\/blood-2007-06-093906"},{"key":"2982_CR12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM et al (2016) Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127:208\u2013215","journal-title":"Blood"},{"key":"2982_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Tam CS, O\u2019Brien SM et al (2016) Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127:303\u2013309","journal-title":"Blood"},{"key":"2982_CR14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W et al (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975\u2013980","journal-title":"Blood"},{"issue":"26","key":"2982_CR15","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer K, Cramer P, Busch R et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30(26):3209\u20133216","journal-title":"J Clin Oncol"},{"issue":"7","key":"2982_CR16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink A-M, Bahlo J et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928\u2013942","journal-title":"Lancet Oncol"},{"key":"2982_CR17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101\u20131110","journal-title":"N Engl J Med"},{"issue":"9980","key":"2982_CR18","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A et al (2015) Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 385(9980):1873\u20131883","journal-title":"Lancet"},{"key":"2982_CR19","first-page":"1","volume":"10","author":"T Robak","year":"2016","unstructured":"Robak T, Warzocha K, Babu G et al (2016) Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 10:1\u20139","journal-title":"Leuk Lymphoma"},{"key":"2982_CR20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutr\u00e9 SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32\u201342","journal-title":"N Engl J Med"},{"key":"2982_CR21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","volume":"159","author":"D Oscier","year":"2012","unstructured":"Oscier D, Dearden C, Eren E et al (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 159:541\u2013564","journal-title":"Br J Haematol"},{"key":"2982_CR22","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, D\u00f6hner H, Ritgen M et al (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 116:2438\u20132447","journal-title":"Blood"},{"key":"2982_CR23","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","volume":"117","author":"IF Khouri","year":"2011","unstructured":"Khouri IF, Bassett R, Poindexter N et al (2011) Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 117:4679\u20134688","journal-title":"Cancer"},{"key":"2982_CR24","unstructured":"Sorror ML, Storer B, Sandmaier BM, et al. (2010) Impacts of cytogenetic abnormalities and prior alemtuzumab on outcomes of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). [abstract 2364] Blood 116:2364. Available at: http:\/\/www.bloodjournal.org\/content\/116\/21\/2364 . Accessed January 2, 2016."},{"key":"2982_CR25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","volume":"27","author":"JR Brown","year":"2013","unstructured":"Brown JR, Kim HT, Armand P et al (2013) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27:362\u2013369","journal-title":"Leukemia"},{"key":"2982_CR26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2012.09170.x","volume":"158","author":"CL Toze","year":"2012","unstructured":"Toze CL, Dalal CB, Nevill TJ et al (2012) Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 158:174\u2013185","journal-title":"Br J Haematol"},{"key":"2982_CR27","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3109\/10428194.2013.836598","volume":"55","author":"K Hebenstreit","year":"2014","unstructured":"Hebenstreit K, Iacobelli S, Leiblein S et al (2014) Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. Leuk Lymphoma 55:1274\u20131280","journal-title":"Leuk Lymphoma"},{"key":"2982_CR28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","volume":"21","author":"P Dreger","year":"2007","unstructured":"Dreger P, Corradini P, Kimby E et al (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12\u201317","journal-title":"Leukemia"},{"key":"2982_CR29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","volume":"25","author":"I Herth","year":"2014","unstructured":"Herth I, Dietrich S, Benner A et al (2014) The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 25:200\u2013206","journal-title":"Ann Oncol"},{"issue":"12","key":"2982_CR30","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","volume":"22","author":"MA Kharfan-Dabaja","year":"2016","unstructured":"Kharfan-Dabaja MA, Kumar A, Hamadani M et al (2016) Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines Committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant 22(12):2117\u20132125","journal-title":"Biol Blood Marrow Transplant"},{"key":"2982_CR31","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","volume":"124","author":"P Dreger","year":"2014","unstructured":"Dreger P, Schetelig J, Andersen N et al (2014) Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 124:3841\u20133849","journal-title":"Blood"},{"key":"2982_CR32","doi-asserted-by":"crossref","unstructured":"Ryan CE, Sahaf B, Logan AC, et al. (2016) Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood 128:2899\u20132908","DOI":"10.1182\/blood-2016-06-715284"},{"key":"2982_CR33","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","volume":"30","author":"BD Cheson","year":"2012","unstructured":"Cheson BD, Byrd JC, Rai KR et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30:2820\u20132822","journal-title":"J Clin Oncol"},{"key":"2982_CR34","unstructured":"U.S. Food and Drug Administration. FDA News Release: FDA approves Imbruvica to treat chronic lymphocytic leukemia. Silver Spring, MD: U.S. Department of Health and Human Services; 2014. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm385764.htm . Accessed August 29, 2016."},{"key":"2982_CR35","unstructured":"U.S. Food and Drug Administration. FDA News Release: FDA expands approved use of Imbruvica for chronic lymphocytic leukemia. Silver Spring, MD: U.S. Department of Health and Human Services; 2014. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm406916.htm . Accessed August 29, 2016."},{"key":"2982_CR36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31:88\u201394","journal-title":"J Clin Oncol"},{"key":"2982_CR37","doi-asserted-by":"crossref","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, et al; for the RESONATE Investigators (2014) Ibrutinib versus of atumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213\u2013223","DOI":"10.1056\/NEJMoa1400376"},{"key":"2982_CR38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutr\u00e9 SE et al (2015) Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2497\u20132506","journal-title":"Blood"},{"key":"2982_CR39","doi-asserted-by":"crossref","unstructured":"Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A. Atrial fibrillation in CLL\/SLL patients on ibrutinib. [abstract 2933] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5\u20138, 2015; Orlando, USA. Available at: http:\/\/www.bloodjournal.org\/content\/126\/23\/2933 . Accessed April 4, 2016.","DOI":"10.1182\/blood.V126.23.2933.2933"},{"key":"2982_CR40","unstructured":"Shanafelt TD, Chaffee KG, Call TG, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). [abstract 2950] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5\u20138, 2015; Orlando, USA. Available at: https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper82991.html . Accessed January 26, 2016. 37"},{"key":"2982_CR41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C et al (2016) The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood 128:138\u2013140 38","journal-title":"Blood"},{"key":"2982_CR42","unstructured":"Imbruvica (ibrutinib) product monograph. Janssen Inc. July 19, 2016."},{"key":"2982_CR43","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373:2425\u20132437","journal-title":"N Engl J Med"},{"key":"2982_CR44","unstructured":"Cramer P, Chanan-Khan A, Fraser G, et al. Ibrutinib combined with bendamustine\/rituximab (BR) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): safety analysis in the HELIOS trial. [abstract 102] Presented at the 16th International Workshop on Chronic Lymphocytic Leukaemia; September 7\u20139, 2015; Sydney, Australia."},{"key":"2982_CR45","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZH, Tian X et al (2015) Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 100:1571\u20131578","journal-title":"Haematologica"},{"key":"2982_CR46","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","volume":"126","author":"C Sun","year":"2015","unstructured":"Sun C, Tian X, Lee YS et al (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 126:2213\u20132219","journal-title":"Blood"},{"key":"2982_CR47","unstructured":"Barrientos JC, O\u2019Brien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE\u2122 study of ibrutinib vs ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. [abstract 4696] Presented at the 56th Annual Meeting and Exposition of the American Society of Hematology; December 6\u20139, 2014; San Francisco, USA. Available at: https:\/\/ash.confex.com\/ash\/2014\/webprogram\/Paper67774.html . Accessed February 24, 2016."},{"key":"2982_CR48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","volume":"30","author":"KA Rogers","year":"2016","unstructured":"Rogers KA, Ruppert AS, Bingman A et al (2016) Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 30:346\u2013350","journal-title":"Leukemia"},{"key":"2982_CR49","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman SE, Gordon AL, Wagner AJ et al (2010) Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116:2078\u20132088","journal-title":"Blood"},{"key":"2982_CR50","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Q Yang","year":"2015","unstructured":"Yang Q, Modi P, Newcomb T, Qu\u00e9va C, Gandhi V (2015) Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 21:1537\u20131542","journal-title":"Clin Cancer Res"},{"key":"2982_CR51","unstructured":"U.S. Food and Drug Administration. FDA News Release: FDA approves Zydelig for three types of blood cancers. Silver Spring, MD: U.S. Department of Health and Human Services; 2014. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm406387.htm . Accessed Sept 9, 2016."},{"key":"2982_CR52","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutr\u00e9 SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997\u20131007","journal-title":"N Engl J Med"},{"key":"2982_CR53","unstructured":"Sharman JP, Coutr\u00e9 SE, Furman RR, et al. (2014) Second interim analysis of a phase 3 study of idelalisib (ZYDELIG\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del (17p) and other adverse prognostic factors. [abstract 330] Blood 124:330. Available at: http:\/\/www.bloodjournal.org\/content\/124\/21\/330 . Accessed December 14, 2015."},{"key":"2982_CR54","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"SM O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ et al (2015) A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia. Blood 126:2686\u20132694","journal-title":"Blood"},{"key":"2982_CR55","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","volume":"39","author":"CY Louie","year":"2015","unstructured":"Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39:1653\u20131660","journal-title":"Am J Surg Pathol"},{"key":"2982_CR56","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutr\u00e9","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR et al (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56:2779\u20132786","journal-title":"Leuk Lymphoma"},{"key":"2982_CR57","unstructured":"Gilead Sciences Inc. Decreased overall survival and increased risk of serious infections in patients receiving ZYDELIG (idelalisib). March 21, 2016. Available at: http:\/\/zydelig.com\/Content\/pdf\/Zydelig-Safety-Info-FINAL.pdf . Accessed April 4, 2016."},{"key":"2982_CR58","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF et al (2016) The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 127:3215\u20133224","journal-title":"Blood"},{"key":"2982_CR59","unstructured":"U.S. Food and Drug Administration. FDA News Release: FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. Silver Spring, MD: U.S. Department of Health and Human Services; 2016. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm495253.htm . Accessed Sept 9, 2016."},{"key":"2982_CR60","unstructured":"Seymour JF, Davids MS, Pagel JM, et al. (2013) Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). [abstract 872] Blood 122:872. Available at: http:\/\/www.bloodjournal.org\/content\/122\/21\/872 . Accessed December 14, 2015."},{"key":"2982_CR61","unstructured":"Roberts A, Ma S, Brander D, et al. Venetoclax (ABT-199\/GDC-0199) combined with rituximab induces deep responses in patients with relapsed\/refractory chronic lymphocytic leukemia. [abstract S431] Presented at the 20th Congress of the European Hematology Association; June 11\u201314, 2015; Vienna, Austria. Available at: http:\/\/learningcenter.ehaweb.org\/eha\/2015\/20th\/103125\/ . Accessed April 4, 2016."},{"key":"2982_CR62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311\u2013322","journal-title":"N Engl J Med"},{"key":"2982_CR63","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17:768\u2013778","journal-title":"Lancet Oncol"},{"key":"2982_CR64","unstructured":"Fraser G, Cramer P, Demirkan F, et al. Ibrutinib plus bendamustine and rituximab in previously treated chronic lymphocytic leukemia\/small lymphocytic leukemia (CLL\/SLL): 2-year follow-up including MRD from the HELIOS study. [abstract S430] Presented at the 21st Congress of the European Hematology Association; June 9\u201312, 2016; Copenhagen, Denmark. Available at: http:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/135186\/ . Accessed July 19, 2016."},{"key":"2982_CR65","unstructured":"Sorenson S, Tam C, Diels J et al Indirect comparison of ibrutinib versus idelalisib plus ofatumumab in patients with previously treated chronic lymphocytic leukemia [poster]. XVI International Workshop on Chronic Lymphocytic Leukaemia; September 7\u20139, 2015; Sydney. Australia"},{"key":"2982_CR66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G et al (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1:80\u201387","journal-title":"JAMA Oncol"},{"key":"2982_CR67","unstructured":"O\u2019Brien SM, Byrd JC, Hillmenn P, et al. Outcomes with ibrutinib by line of therapy in patients with CLL: analyses from phase III data. [abstract 7520] Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology; June 3\u20137, 2016; Chicago, USA. Available at: http:\/\/meetinglibrary.asco.org\/content\/164543-176 . Accessed August 29, 2016."},{"key":"2982_CR68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, Furman RR, Coutre SE et al (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol 15:48\u201358","journal-title":"Lancet Oncol"},{"key":"2982_CR69","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM et al (2014) Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286\u20132294","journal-title":"N Engl J Med"},{"key":"2982_CR70","unstructured":"Mato A, Nabhan C, Barr PM, et al. Favorable outcomes in CLL pts with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study. [abstract 719] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5\u20138, 2015; Orlando, USA. Available at: https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper80707.html . Accessed January 26, 2016."},{"key":"2982_CR71","doi-asserted-by":"crossref","unstructured":"Jones J, Mato AR, Coutre S, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. [abstract 715] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5\u20138, 2015; Orlando, USA. Available at: https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper81347.html . Accessed January 1, 2016.","DOI":"10.1182\/blood.V126.23.715.715"},{"key":"2982_CR72","unstructured":"U.S. Food and Drug Administration. FDA statement: FDA halts clinical trial of drug Revlimid (lenalidomide) for chronic lymphocytic leukemia due to safety concerns. Silver Spring, MD: U.S. Department of Health and Human Services; 2013. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm361444.htm . Accessed January 2, 2016."},{"key":"2982_CR73","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S et al (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:323\u2013332","journal-title":"N Engl J Med"},{"key":"2982_CR74","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F et al (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17:200\u2013211","journal-title":"Lancet Oncol"},{"key":"2982_CR75","unstructured":"Zelenetz AD, Robak T, Coiffier B, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed\/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. [abstract LBA-5] Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology; December 5\u20138, 2015; Orlando, USA. Available at: https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper87420.html . Accessed February 24, 2016."},{"key":"2982_CR76","unstructured":"Jones JA, Robak T, Wach M, et al. Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). [abstract 7515] Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology; June 3\u20137, 2016; Chicago, USA. Available at: http:\/\/meetinglibrary.asco.org\/content\/163777-176 . Accessed November 16, 2016."},{"key":"2982_CR77","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM, Saylors GB, Spurgeon SE et al (2016) Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127:2411\u20132415","journal-title":"Blood"},{"key":"2982_CR78","unstructured":"Davids MS, Kim HT, Bsat J, et al. Preliminary results of a phase II study of ibrutinib in combination with FCR (iFCR) in previously untreated, younger patients with CLL. [abstract P210] Presented at the 21st Congress of the European Hematology Association; June 9\u201312, 2016; Copenhagen, Denmark. Available at: http:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/133198\/ . Accessed August 29, 2016."},{"key":"2982_CR79","doi-asserted-by":"crossref","unstructured":"Oppermann S, Ylanko J, Shi Y et al (2016) High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 128:934\u2013947","DOI":"10.1182\/blood-2015-12-687814"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2982-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2982-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2982-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:41:18Z","timestamp":1719150078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2982-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2982"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2982-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}